The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases – recommendations of the IRDiRC Data Mining and Repurposing Task Force
Authors:
- on behalf of the IRDiRC Data Mining and Repurposing Task ForceOFon behalf of the IRDiRC Data Mining and Repurposing Task Force
- Noel T SouthallNSNoel T Southall
Open Access
- 15 October 2019
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 14 (1) , 1-8
Abstract
The number of available therapies for rare diseases remains low, as fewer than 6% of rare diseases have an approved treatment option. The International Rare Diseases Research Consortium (IRDiRC) set up the multi-stakeholder Data Mining and Repurposing (DMR) Task Force to examine the potential of applying biomedical data mining strategies to identify new opportunities to use existing pharmaceutical compounds in new ways and to accelerate the pace of drug development for rare disease patients. In reviewing past successes of data mining for drug repurposing, and planning for future biomedical research capacity, the DMR Task Force identified four strategic infrastructure investment areas to focus on in order to accelerate rare disease research productivity and drug development: (1) improving the capture and sharing of self-reported patient data, (2) better integration of existing research data, (3) increasing experimental testing capacity, and (4) sharing of rare disease research and development expertise. Additionally, the DMR Task Force also recommended a number of strategies to increase data mining and repurposing opportunities for rare diseases research as well as the development of individualized and precision medicine strategies.Keywords
Funding Information
- FP7 Research infrastructures (305207)
This publication has 39 references indexed in Scilit:
- Graph Theory Enables Drug Repurposing – How a Mathematical Model Can Drive the Discovery of Hidden Mechanisms of ActionPLOS ONE, 2014
- Multifaceted roles of ultra-rare and rare disease patients/parents in drug discoveryDrug Discovery Today, 2013
- Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseasesDrug Design, Development and Therapy, 2013
- Open PHACTS: semantic interoperability for drug discoveryDrug Discovery Today, 2012
- Rare-disease project has global ambitionsNature, 2011
- Patient-reported Outcomes as a Source of Evidence in Off-Label Prescribing: Analysis of Data From PatientsLikeMeJournal of Medical Internet Research, 2011
- Accelerating orphan drug developmentNature Reviews Drug Discovery, 2010
- Sharing Health Data for Better Outcomes on PatientsLikeMeJournal of Medical Internet Research, 2010
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004